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Purpose: To provide a fast computational method, based on the proximal graph solver (POGS) - a convex
optimization solver using the alternating direction method of multipliers (ADMM), for calculating an optimal
treatment plan in rotating shield brachytherapy (RSBT). RSBT treatment planning has more degrees of
freedom than conventional high-dose-rate brachytherapy due to the addition of emission direction, and this
necessitates a fast optimization technique to enable clinical usage.
Methods: The multi-helix RSBT (H-RSBT) delivery technique1 was considered with five representative
cervical cancer patients. Treatment plans were generated for all patients using the POGS method and the
previously considered commercial solver IBM ILOG CPLEX2. The rectum, bladder, sigmoid colon, high-risk
clinical target volume (HR-CTV), and HR-CTV boundary were the structures considered in our optimization
problem, which is called the asymmetric dose-volume optimization with smoothness control. Dose calculation
resolution was 1×1×3mm3 for all cases. The H-RSBT applicator has 6 helices, with 33.3 mm of translation
along the applicator per helical rotation and 1.7 mm spacing between dwell positions, yielding 17.5◦emission
angle spacing per 5 mm along the applicator.
Results: For each patient, HR-CTV D90, HR-CTV D100, rectum D2cc, sigmoid D2cc, and bladder D2cc
matched within 1% for CPLEX and POGS methods. Also, we obtained similar EQD2 figures between CPLEX
and POGS methods. POGS was around 18 times faster than CPLEX. Over all patients, total optimization
times were 32.1-65.4 seconds for CPLEX and 2.1-3.9 seconds for POGS.
Conclusions: POGS substantially reduced treatment plan optimization time around 18 times for RSBT
with similar HR-CTV D90, organ at risk (OAR) D2cc values, and EQD2 figure relative to CPLEX, which is
significant progress toward clinical translation of RSBT. POGS is also applicable to conventional high-dose-
rate brachytherapy.
Keywords: Brachytherapy, rotating shield brachytherapy, gynecological cancer, cancer treatment planning,
optimization
I. INTRODUCTION
High-dose-rate brachytherapy (HDR-BT) involves
placing a radiation source inside of or adjacent to a
target organ, i.e., tumor. Conventional HDR-BT uses
an unshielded brachytherapy source with a radially-
symmetric dose distribution3,4, which limits the inten-
sity modulation capacity of the approach. Rotating-
shield brachytherapy (RSBT) has a rotating radiation-
attenuating shield around a brachytherapy source. The
RSBT concepts for single-catheter treatment5 and multi-
catheter treatment6 were introduced by Ebert in 2002
and 2006 respectively.
In the multi-helix RSBT (H-RSBT) treatment, a ra-
diation source travels inside a brachytherapy applicator
having helical keyways. While moving along the applica-
tor for a given keyway, the partial shield rotates around
the radiation source simultaneously. In traveling along
a)Author to whom correspondence should be addressed. Electronic
mail: xiaodong-wu@uiowa.edu
each keyway, the radiation source stops at designated lo-
cations called dwell positions. By adjusting the distance
between adjacent dwell positions, the rotation angle of
the partial shield is determined accordingly. Intensity
modulated dose distributions can be delivered to the tar-
get with reduced dose exposure to non-target organs by
controlling the treatment time in an optimal manner for
each dwell position. Hence, it is reported that a radiation
source with rotating shields can deliver more conformal
dose distributions than an unshielded radiation source.1
HDR-BT treatment plans are often generated using in-
verse planning tools7–13. Based on the given clinical pre-
scription, various optimization problems were introduced
previously ranging from minimizing treatment time un-
der restrictions14,15 to minimizing dose error7,12,13,16. In-
verse planning by simulated annealing (IPSA)7 is a well
known method to optimize the dose volume histogram
(DVH) directly with given constraints. The BrachyVi-
sion treatment planning system (Varian Medical System
Inc., Palo Alto, CA) uses this type of DVH-based opti-
mization algorithm.12
Unlike the conventional HDR-BT optimization, the
RSBT optimization problem has the additional optimiza-
2tion variables of radiation exposure time at each angle of
the shield. Due to the increased degrees of freedom in
RSBT, RSBT optimization is more difficult than that for
the conventional HDR-BT. In addition, there is a com-
pelling need to quickly obtain optimal treatment plans
in RSBT to enable clinical usage. To achieve this, re-
searchers have used the dose-surface optimization (DSO)
method17,18, which minimizes the total dose errors over
only voxels on the HR-CTV surface. Instead of dealing
with only voxels on the HR-CTV surface, Liu et al.19
defined the region of interest in tumor which includes
the surface of HR-CTV as well as the inside voxels of
tumor. Additionally, the authors used the total varia-
tion (TV) norm penalty in their optimization problem to
make smooth changes in the emission times of adjacent
beams in the treatment process to facilitate the efficient
delivery of an RSBT plan. This optimization problem
for RSBT is called asymmetric dose-volume optimization
with smoothness control (ADOS).
In this paper, we consider the ADOS optimization
problem. A fast computational method is proposed to
solve the ADOS optimization problem for the optimal
cancer treatment planning for RSBT. Liu et al. used a
commercial optimization solver called CPLEX19. In or-
der to efficiently solve the ADOS optimization problem,
which is a large-scale RSBT optimization problem, we
designed an optimization method based on the proximal
graph solver (POGS)20, which is a solver using the alter-
nating direction method of multipliers (ADMM). For us-
ing POGS, we derived closed-form formulas for the prox-
imal operators used in POGS. Further, we applied our
method to the H-RSBT, which is a mechanically-feasible
delivery technique for RSBT proposed by Dadkhah et
al.
1. In the numerical experiments, we considered cervi-
cal cancer, even though our method is also applicable to
other types of cancer such as breast cancer and prostate
cancer.
II. MATERIALS AND METHODS
A. Delivery method
In order to deliver the radiation dose to a target organ,
we consider a mechanically-feasible delivery technique for
RSBT, called the multi-helix RSBT (H-RSBT)1. Fig.
1 shows the illustration of the H-RSBT method. The
shield opening is represented by the azimuthal and zenith
emission angles, denoted by ∆ϕ and ∆θ respectively.
In H-RSBT, a Xoft Axxent radiation source, inside its
cooling catheter, with a freely-rotating partial radiation
shield is translated inside an applicator with six helical
keyways carved out of the inner wall. The six keyways
are evenly spaced on the applicator cross section, by 60◦,
and each keyway has a helical pitch of one rotation per
33.3 mm of translation. The partial shield has a protrud-
ing key that travels down a given keyway, and, due to the
helical design of the keyways, the shield rotates about the
radiation source as the source catheter is translated, and
the emission angle of the shield is known for a given key-
way and translational dwell position. As the H-RSBT ap-
plicator has 6 helices, with 33.3 mm of translation along
the applicator per helical rotation and 1.7 mm spacing
between dwell positions, it yields 17.5◦of rotation for the
shield per 5 mm (standard dwell position spacing) of its
translation along the applicator. The dose calculation
resolution was 1×1×3mm3 for all cases. The transmis-
sion through the shield is 0.1% and approximated to be
0% for the dose calculation. For each patient considered,
45◦azimuthal emission angle was used for treatment plan-
ning. The zenith emission angle of the modeled shields
was an asymmetric 116◦, which is consistent with previ-
ous work.1
B. Radiation source model and dose calculation
For H-RSBT, the delivery is parameterized by keyway
number and dwell position number along the keyway. To
quantitatively describe the structure of high-dose-regions
formed by a partially shielded source, we introduce the
notation of beamlet. A beamlet, denoted by Di(j, b), is
defined as the dose rate at point ~ri with the shielded
source positioned at the j-th dwell position while the
shield is aligned with the b-th keyway.
To calculate the beamlet, we use the TG-43 dose
calculation model of Rivard et al.21. The radiation
source is assumed to be partially shielded 50kVp Xoft
AxxentTM (Sunnyvale, CA). To be consistent with previ-
ous work17,18,22, we consider that the dose to the points
blocked by the shield is 0, since the transmission rate
from 50kVp Xoft AxxentTM can be controlled to be less
than 0.1% when using a 0.5 mm tungsten shield.17,18
Then, we can quantify the radiation dose amount at the
point ~ri, denoted by di, as a time-weighted sum of all
beamlets as follows:
di =
∑
j,b
Di(j, b)tj,b, (1)
where tj,b is the duration time of the beamlet Di(j, b).
In the next subsection, we introduce the RSBT opti-
mization problem having asymmetric penalty parameters
for HR-CTV and organs at risk (OARs), with TV regula-
tion term for smoothness in the beamlet emission times.
C. Optimization problem for cancer treatment planning in
RSBT
1. Problem formulation
Let t ∈ Rmn×1 be the beamlet emission time vec-
tor for all keyways and all dwell positions, where m
and n are the number of keyways, i.e, m = 6, and
the number of dwell positions along a keyway respec-
tively. We can obtain t by vectorizing tj,b in Eqn. (1);
3FIG. 1. (a) Illustration of multihelix rotating shield brachytherapy (H-RSBT) system. (b) Partially shielded radiation source.
namely, the vector t ∈ Rmn×1 is a concatenated vec-
tor, which is expressed as t = [t[1]T , t[2]T , ..., t[m]T ]T ,
where t[j] ∈ Rn×1 is the dwell time vector for all the
beamlets along a keyway, and the super-script T repre-
sents the transpose. Let us define a concatenated dose
rate matrix D = [D[1], D[2], ..., D[m]] ∈ Rl×mn, where
D[j] ∈ Rl×n, j = 1, ...,m, is the dose rate matrix for
the j-th selected keyway, and l is the number of voxels
that we are interested in. We denote the whole index
set for voxels of interest (VOIs) as IV OIs and the index
set for HR-CTV, bladder, rectum, sigmoid, and normal
tissue around the HR-CTV as Itumor, Ibladder, Irectum,
Isigmoid, and Inormal respectively. The dose rate ma-
trix D has information about dose rate delivered to each
tissue point in IV OIs from each beamlet.
We consider the following RSBT optimization problem
having a quadratic objective function with total variation
(TV) regulation term for smooth beamlet emission times:
minimize
t∈Rmn,d∈Rl
∑
i∈IV OIs
h(di) +
m∑
j=1
β||Lt[j]||1
subject to Dt = d,
t ≥ 0, (2)
where D ∈ Rl×mn is a dose rate matrix, t ≥ 0 is the
element-wise non-negative emission time, di, which is the
i-th element of d, is the dose amount at the i-th voxel as
introduced in Eqn. (1). In Eqn. (2),
h(di) , (λ
+
i H(di − dˆi) + λ
−
i H(dˆi − di))(di − dˆi)
2,
where H(x) is the unit step function, which is H(a) =
1 if a > 0, and H(a) = 0 if a ≤ 0, and λ+i and λ
−
i
represent overdose and underdose penalty parameters for
the i-th voxel respectively. L ∈ Rn×n is the matrix which
calculates TV norm of a vector; namely, L is defined as
follows:
L ,


1 −1 0 0 ... 0 0
0 1 −1 0 ... 0 0
0 0 1 −1 ... 0 0
...
...
...
...
...
...
...
0 0 0 0 ... 1 −1
0 0 0 0 ... 0 0


.
dˆi is a prescribed dose amount for the i-th voxel. dˆi can
have a different value for each VOI. For example, dˆi =
dˆtumor if i ∈ Itumor, and dˆi = dˆbadder if i ∈ Ibladder. We
denote the prescribed dose amount for HR-CTV, bladder,
rectum, sigmoid, and normal tissue around the HR-CTV
as dˆtumor, dˆbladder , dˆrectum, dˆsigmoid, and dˆnormal. For
λ+i and λ
−
i , we use different non-negative overdose and
underdose parameter values including 0.
The TV norm alleviates the positioning uncertainty
in the treatment process. If we have two dramatically
different emission times tj,b and tj+1,b between two ad-
jacent beamlets along the same keyway, a small error in
the dwell positions may cause an unacceptable treatment
result. By applying the smoothness term between two ad-
jacent beamlets along the same keyway in H-RSBT, we
can reduce the treatment error caused by the positioning
uncertainty in the treatment process.
Since we use different penalty parameter values for the
overdose and underdose of a voxel, we call Eqn. (2) as
RSBT optimization problem having asymmetric penalty
parameters or simply ADOS.
2. POGS implementation
In order to simplify the sum of the TV norms in Eqn.
(2), let us introduce a matrix L¯ , Im×m ⊗ L, where ⊗
is the Kronecker product, and Im×m is an m ×m iden-
tity matrix. By assigning L¯t = y and introducing the
4indicator function I(·), we restate Eqn. (2) as follows:
minimize
t,y∈Rmn,d∈Rl
∑
i∈IV OIs
h(di) + β||y||1 + I(x ≥ 0)
subject to Dt = d,
L¯t = y, (3)
where D ∈ Rl×mn, L¯ ∈ Rmn×mn, and I(t ≥ 0) is the
element-wise indicator function; namely, I(ti ≥ 0) = 0 if
ti ≥ 0, and I(ti ≥ 0) =∞ if ti < 0.
By letting
A =
(
D
L¯
)
, z =
(
d
y
)
,
we can further simplify Eqn. (3) into
minimize
t∈Rmn,z∈Rl+mn
l∑
i=1
h(zi) + β||z[l+1:l+mn]||1 + I(t ≥ 0)
subject to At = z, (4)
where z[a:b] is the partial vector of z by taking vector z
from the a-th element to the b-th element. We define the
following functions:
g(t) = I(t ≥ 0), (5)
f(z) =
l∑
i=1
h(zi) + β||z[l+1:l+mn]||1. (6)
Then we turn Eqn. (4) into a graph-form convex opti-
mization problem20, where the constraint is z = At, and
A = [DT L¯T ]T ∈ R(l+mn)×mn. We have derived the de-
tailed updating rules for each optimization variable in
the POGS solver for Eqn. (4). We introduce our derived
results in detail for the proximal operators used in the
POGS solver, updating steps, and stopping criteria as
follows.
The POGS updates primal variables, conducts the pro-
jection onto the space z = At, and then, updates dual
variables iteratively until the stopping criteria are satis-
fied or the maximum number of iterations, denoted by
MaxItr, is reached. The primal variable and dual vari-
able are updating variables to be used for optimality con-
dition in the algorithm. For the primal variable, dual
variable, and projection result, we used (tˆ, zˆ), (t, z), and
(t˜, z˜) respectively. We introduce each updating steps in
detail for our optimization problem in Eqn. (4). We use
the super-script k to represent the k-th iteration.
Updating primal variables tˆk+1 and zˆk+1: In up-
dating the primal variables, we use the following proximal
operators with a penalty parameter ρ:
tˆk+1 = Proxg(t
k − t˜k)
= argmin
t
I(t ≥ 0) +
ρ
2
||t− (tk − t˜k)||2,
zˆk+1 = Proxf (z
k − z˜k)
= argmin
z
l∑
i=1
h(zi) + β||z[l+1:l+mn]||1
+
ρ
2
||z − (zk − z˜k)||2.
The proximal operator is used to make a compromise be-
tween the solution at the k-th iteration and the function
value with the solution at the k+1 iteration. We are able
to explicitly derive closed-form formulas for the proximal
operators. For tˆk+1 ∈ Rmn, we have
tˆk+1 = max(tk − t˜k,0), (7)
where max(a, b) provides the maximum value between a
and b element-wise. For zˆk+1i , 1 ≤ i ≤ l, we also derive
zˆk+1i =


zki − z˜
k
i −
β
ρ
, if zki − z˜
k
i >
β
ρ
zki − z˜
k
i +
β
ρ
, if zki − z˜
k
i < −
β
ρ
0, otherwise
. (8)
For zˆk+1i , l + 1 ≤ i ≤ l +mn, we obtain
zˆk+1i =


2λ+
i
dˆi+ρ(z
k
i
−z˜k
i
)
2λ+
i
+ρ
, if zki − z˜
k
i ≥ dˆi,
2λ−
i
dˆi+ρ(z
k
i
−z˜k
i
)
2λ−
i
+ρ
, if zki − z˜
k
i < dˆi.
. (9)
POGS uses the adaptive value for ρ as default to further
increase the convergence speed.
Projection onto z = At from (tˆk+1+ t˜k, zˆk+1+ z˜k):
The projection operation is mapping the primal variables
to the closest feasible solution. The projected variables
onto z = At from (tˆk+1 + t˜k, zˆk+1 + z˜k), denoted as tk+1
and zk+1, are obtained by solving the following optimiza-
tion:
minimize
t,z
1
2
||t− (tˆk+1 + t˜k)||22 +
1
2
||z − (zˆk+1 + z˜k)||22
subject to At = z
By solving this optimization and using Lagrange
conditions23, we have the following formulation:
(
tk+1
zk+1
)
=
(
I AT
A −I
)−1(
tˆk+1 + t˜k +AT (zˆk+1 + z˜t)
0
)
.
Updating dual variables t˜k+1 and z˜k+1: We obtain
the dual variable at iteration (k+1) by updating the dual
variable at the k-th iteration as follows:
t˜k+1 = t˜k + tˆk+1 − tk+1,
z˜k+1 = z˜k + zˆk+1 − zk+1.
5Algorithm 1: Fast treatment planning for RSBT in
POGS implementation
Input: A ∈ R(l+mn)×mn, MaxItr, λ+, λ−, dˆ ∈ Rl, β
Output: t
Initialize: k ← 0, tk ← 0, zk ← 0, t˜← 0,z˜ ← 0
for k = 1 to MaxItr do
Updating primal variables tˆk+1, zˆk+1:
tˆk+1 ← Proxg(tk − t˜k) ⊲ See (7)
zˆk+1 ← Proxf (z
k
− z˜k) ⊲ See (8) and (9)
Projection onto z = At:(
tk+1
zk+1
)
←
(
I AT
A −I
)
−1 (
tˆk+1 + t˜k +AT (zˆk+1 + z˜t)
0
)
Updating dual variables t˜k+1, z˜k+1:
t˜k+1 ← t˜k + tˆk+1 − tk+1
z˜k+1 ← z˜k + zˆk+1 − zk+1
if Stopping criteria are met then
break
end
end
We summarize the updating steps in Algorithm 1.
Stopping criteria: For the stopping criteria, we de-
fine the primal and dual residuals as follows:
||Atˆk+1 − zˆk+1||2 ≤ ǫ
pri,
||AT vˆk+1 + µˆk+1||2 ≤ ǫ
dual, (10)
where vˆk+1 = −ρ(zˆk+1 − zk + z˜k), µˆk+1 = −ρ(tˆk+1 −
tk + t˜k). Here, ǫpri and ǫdual are positive tolerances for
primal and dual residuals respectively:
ǫpri = ǫabs + ǫrel||zˆk+1||2,
ǫdual = ǫabs + ǫrel||µˆk+1||2, (11)
where we used (ǫabs, ǫrel) = (10−4, 10−2) in the numerical
experiments.
D. Treatment planning
Five patients with cervical cancer were considered,
whose HR-CTV volumes range from 42.2 to 98.8 cm3.
Table I shows the volume and maximum dimension of
HR-CTV for five patients. All the HR-CTVs and OARs
were manually contoured by physicians on T2 weighted
1×1×3mm3 resolution MR images taken with a Siemens
MAGNETOM 3T scanner (Siemens, Germany) at the
beginning of the first fraction of brachytherapy. A tita-
nium Fletcher-Suit-Delclos style tandem and ovoids (Var-
ian Medical Systems, Palo Alto, CA) were used as the
brachytherapy applicator. We used the same datasets
as the previous research conducted by Liu et al.19 and
Dadkhah et al.1.
All the patients had external beam radiation treat-
ment in 25 fractions at 1.8 Gy/fraction. We assume that
the external beam radiotherapy dose was uniformly de-
livered to the HR-CTV and OARs for all the patient
cases. The dose in each voxel was converted to equivalent
dose in 2 Gy per fraction of external radiation therapy
TABLE I. HR-CTV volumes and dimensions for all patients
Patient Num. HR-CTV vol-
ume (cm3)
HR-CTV maximum
dimension (cm)
Case 1 42.2 6.3
Case 2 45.8 7.4
Case 3 78.0 8.6
Case 4 98.8 9.6
Case 5 75.0 7.5
Avg. 68.0 7.9
SDa 23.8 1.8
a
Standard Deviation
(EQD2) using the linear quadratic model,24 where the
linear-quadratic parameter, α/β, is set to 3 Gy for OARs
and 10 Gy for HR-CTV.
For VOIs, we define the voxels located at a distance
between 3 mm and 20 mm to the radiation source path
or those within 10 mm inside and outside of the HR-
CTV boundary surface.19 We deal with the HR-CTV,
HR-CTV boundary, bladder, sigmoid, and rectum inside
of VOIs in our optimization problem. The optimization
parameter settings are shown in Table II.
For all the brachytherapy treatment plans, we esca-
lated the EQD2 of the HR-CTV without exceeding the
D2cc tolerance of the bladder, rectum, and sigmoid colon.
We used 90 Gy for bladder tolerance, and 75 Gy for rec-
tum and sigmoid colon tolerances according to Groupe
Europe´en de Curiethe´rapie, European Society for Ther-
apeutic Radiology and Oncology (GEC ESTRO).25,26
E. Treatment plan evaluation
Optimized treatment plans were generated for all pa-
tients using the POGS method and the previously con-
sidered CPLEX method.19 The same objective function,
with the same input parameters and beamlets, was mini-
mized for each patient with both methods. A total varia-
tion term was included in the objective function as a reg-
ularization term, resulting in smoothly-varying emission
times along each keyway. The regularization promotes
robustness of the resulting overall dose distribution with
respect to small errors (expected ≤ 1 mm) in source po-
sitioning. The rectum, bladder, sigmoid colon, HR-CTV,
and HR-CTV boundary were the structures considered.
We compared our method with the previous research
conducted by Liu et al.19 using CPLEX2 for H-RSBT.
We evaluated the quality of the delivery plans as well as
the execution time to solve Eqn. (2) with POGS20. Since
Liu et al. compared their method based on CPLEX with
other existing RSBT dose optimization methods ranging
from DSO to IPSA in their previous research19, we only
compared POGS and CPLEX in this paper.
The comparison metrics for the quality of the deliv-
ery plans are the HR-CTV D90, HR-CTV D100, OARs
6TABLE II. Parameter settings
Method dˆtumor dˆbladder dˆrectum dˆsigmoid dˆnormal
a Tumor Bladder Rectum Sigmoid Normal
b
β
λ+i / λ
−
i λ
+
i / λ
−
i λ
+
i / λ
−
i λ
+
i / λ
−
i λ
+
i / λ
−
i
CPLEX 40 25 20 20 40 0/ 2 2/ 0 2/ 0 2/ 0 2/ 0 100
POGS 40 25 20 20 40 0/ 2 2/ 0 2/ 0 2/ 0 2/ 0 100
a Prescribed dose amount for tumor boundary
b Penalty parameter for tumor boundary
TABLE III. Comparison between POGS and CPLEX for 45 ◦azimuthal angle
Case Method
HR-CTV HR-CTV Bladder Rectum Sigmoid Execution
D90 (Gy) D100 (Gy) D2cc (Gy) D2cc (Gy) D2cc (Gy) time (sec.)
Case 1
CPLEX 110.8 54.0 89.9 62.4 75.0 32.1
POGS 111.4 54.0 90.0 64.7 74.7 2.1
Case 2
CPLEX 111.5 44.3 90.0 72.2 54.4 37.0
POGS 111.5 44.3 90.0 71.7 54.8 2.1
Case 3
CPLEX 96.0 44.3 85.9 57.3 75.0 65.4
POGS 95.0 44.3 85.2 55.1 75.0 3.9
Case 4
CPLEX 107.0 55.3 90.0 69.9 54.0 39.4
POGS 106.9 55.4 90.0 69.8 54.0 2.3
Case 5
CPLEX 112.7 44.3 90.0 68.1 59.2 65.4
POGS 112.7 44.3 90.0 68.1 59.2 3.2
Average
CPLEX 107.6 48.4 89.2 66.0 63.5 47.9
POGS 107.5 48.5 89.0 65.9 63.5 2.7
D2cc, DVH, and dose distributions. Since the goal of this
research is achieving a fast solution to the RSBT dose op-
timization problem without compromising the plan qual-
ity, we compared the execution times to solve Eqn. (2)
for all five patient cases. We conducted our numerical ex-
periments on HP Z220 CMT with an Intel Core i7-3770
dual core CPU @3.4GHz clock speed and 16GB DDR3
RAM, using Matlab (R2013b) on the Windows 7 operat-
ing system.
TABLE IV. Dimension of D ∈ Rl×mn in Eqn. (2)
Patient Num. l ×mn
Case 1 54693 × 144
Case 2 51109 × 126
Case 3 79065 × 222
Case 4 50680 × 144
Case 5 59220 × 228
Avg. 58953 × 173
III. RESULTS
Results for five cervical cancer patient cases are shown
in Table III. Table IV shows the dimension of the dose
matrix D in Eqn. (2). Fig. 3 shows the corresponding
DVH in H-RSBT. With the same parameter settings as
in Table II, POGS can achieve an RSBT plan with al-
most the same D90 value (less than 1% difference) as that
achieved by CPLEX in each of the five patient cases. D2cc
values for OARs obtained by POGS are also almost the
same (less than 1% difference) as those from CPLEX. For
the execution time, we achieved around 18 times faster
speed to solve the ADOS problem for H-RSBT than the
CPLEX based method on average. Over all patients, to-
tal optimization times were 32.1-65.4 seconds for CPLEX
and 2.1-3.9 seconds for POGS.
Fig. 2 shows that the EQD2 figures were similar for
each case between CPLEX and POGS.
IV. DISCUSSION
Various treatment planning methods in radiation ther-
apy have been studied. One of the well known methods,
which is called IPSA, was introduced to directly optimize
DVH with given constraints in heuristic way. Due to its
heuristic nature, a global solution is not guaranteed. In-
stead of directly optimizing DVH, we consider the voxel-
wise optimization problem for the RSBT treatment plan-
ning, called ADOS optimization problem, which can be
expressed in a convex optimization problem. We can take
advantage of the convexity to obtain a global solution.
In the ADOS optimization problem, we reduced the
size of the ADOS optimization problem by defining VOIs.
Instead of defining VOIs, the whole voxels can be con-
7FIG. 2. EQD2 dose distributions on MR images for five patient cases obtained from CPLEX and POGS with H-RSBT using
45◦azimuthal angle.
sidered in the optimization problem under the expecta-
tion of better treatment quality with heavy computation.
Since parallel computing and GPU-based high perfor-
mance computing can play an important role in solving
extremely large-scale optimization problems, there is a
rising question about the usability of POGS in paral-
lel computing environment or GPU-based implantation.
The implementation of POGS in such environment is an-
other research work.
In addition, we used a partial shield with 45◦azimuthal
angle in H-RSBT for our numerical experiments. How-
ever, finding the optimal shield angle in H-RSBT is still
an open problem. In order to determine the size of angle
and the radiation exposure time at each angle of shield,
considering both variables in the optimization problem is
also a possible optimization problem.
Finally, POGS (and ADMM) was used in previ-
ous research on intensity-modulated radiation therapy
(IMRT)20,27, fluence map optimization28, and external
beam radiotherapy (EBRT) optimization29. Right at the
time of submitting our journal manuscript, we learned of
the recently-appearing (published on April 12th, 2017)
work29 which applied POGS algorithms to EBRT dose
optimization. The work29 focused on EBRT, while our
paper is the first work to use POGS in brachytherapy, in-
cluding the mechanically-feasible delivery system called
H-RSBT. In our paper, we use TV norm to promote
smoothly-varying emission times along each keyway, such
that the treatment plan is robust to positioning errors of
dwell positions. By comparison, the TV norm is instead
applied to promote the smoothness of the resulting flu-
ence map in the research29 and simplify the delivery. Our
proposed method is applicable to conventional HDR-BT
as well as dynamic modulated brachytherapy30 with sim-
ple modifications, since they share similar mechanisms as
H-RSBT.
V. CONCLUSIONS
POGS substantially reduced treatment plan optimiza-
tion time around 18 times for RSBT with similar HR-
CTVD90, OARD2cc values, and EQD2 figure comparing
to CPLEX, which is significant progress toward clinical
translation of RSBT. Over all cervical cancer patients, to-
tal optimization times were 32.1-65.4 seconds for CPLEX
and 2.1-3.9 seconds for POGS. POGS is also applicable
to conventional high-dose-rate brachytherapy.
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